In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism  by Goodman, William G. et al.
Kidney International, Vol. 50 (1996), pp. 1834—1844
EDITORIAL REVIEW
In vivo assessments of calcium-regulated parathyroid hormone
release in secondary hyperparathyroidism
Disorders of parathyroid gland function are an integral com-
ponent of end-stage renal disease. In the past, secondary hyper-
parathyroidism was an almost invariable consequence of progres-
sive renal insufficiency, and most patients with advanced renal
failure and those undergoing regular dialysis had substantially,
often markedly, elevated serum parathyroid hormone (PTH)
levels [1, 2]. A growing proportion of patients with end-stage renal
disease are now found, however, to have normal or only moder-
ately elevated serum PTH values [3, 4]. Such findings suggest that
recent changes in clinical management have enhanced our ability
to modify the development of secondary hyperparathyroidism in
those with progressive renal disease [4, 5].
Hyperplasia of the parathyroid glands and alterations in the
regulation of PTH release are generally considered to be the two
major determinants of excess PTH secretion in chronic renal
failure. In vitro studies of parathyroid tissues and parathyroid
cells, the application of molecular biology techniques and in vivo
clinical assessments have each provided insight into the regulation
of PTH secretion both in normal and in pathological conditions,
and they have substantially increased our understanding of the
role of certain factors as key modifiers of parathyroid gland
function in chronic renal failure. Less is known, however, about
the regulation of parathyroid cell proliferation and factors that
influence the development of parathyroid gland hyperplasia
[6—81.
Despite a wide range of serum PTH levels that encompasses
both very high and relatively low values, at least for subjects with
renal failure, the secretory behavior of the parathyroid glands is
altered in most patients with end-stage renal disease. Results from
recent clinical investigations have generated controversy, how-
ever, about the precise mechanisms that account for such distur-
bances. The purpose of the current review is to integrate newer
observations from cellular and molecular biology into our current
understanding of parathyroid gland function in chronic renal
failure.
Regulation of PTH secretion
Variations in serum ionized calcium concentration are the
primary determinant of PTH secretion, and serum PTH levels in
vivo are inversely related to the concentration of ionized calcium
in serum. Mayor and Hurst first demonstrated the inverse sigmoi-
dal relationship between serum ionized calcium and PTH levels in
studies of the calf, and their results documented the exquisite
sensitivity of the parathyroids to small variations in ionized
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calcium over periods of several minutes [9]. Therefore, slight
decreases in ionized calcium trigger the release of PTH from the
parathyroid glands, whereas small increases in serum ionized
calcium rapidly diminish PTH release. Such findings have now
been confirmed by a number of investigators in studies of human
subjects [10—13].
The afferent limb—Detecting changes in ionized calcium
The mechanism by which the parathyroid cell detects and
responds to changes in ionized calcium has recently been clarified.
Work by Nemeth et al in studies of dispersed bovine parathyroid
cells in vitro originally demonstrated that changes in the extracel-
lular concentration of calcium, other divalent cations and polyca-
tions elicited rapid changes in intracellular calcium concentration
that were typical of responses activated by membrane-associated
receptors [14—17]. Such findings suggested the existence of a
membrane-associated cation-sensing mechanism, possibly a re-
ceptor, in parathyroid cells. Brown and colleagues subsequently
utilized expression cloning methods to identify a G-protein-
linked, calcium-sensing protein, or calcium receptor, in bovine
parathyroid cells [18].
The bovine parathyroid calcium-receptor binds to extracellular
cations and activates intracellular signal transduction mechanisms
that are directly linked to PTH release [18]. Hydrophobic analysis
indicates that the receptor contains seven membrane-spanning
domains, and sequence analysis has identified several potential
cation-binding sites within a long extracellular domain [18]. The
intracellular portion of the protein contains amino acid sequences
consistent with potential sites of phosphorylation which may
permit regulatory control of receptor activity by G-proteins and
protein kinase C [18].
The human calcium receptor has now been cloned [19, 20], and
the gene encoding the protein has been localized to chromosome
3q. Deletions of a single allele encoding the calcium receptor have
been demonstrated in subjects with familial hypocalciuric hyper-
calcemia (FHH), whereas loss of both alleles leads to the severe,
life-threatening disorder of neonatal hypercalcemia [21]. Activat-
ing mutations in the extracellular domain of the calcium receptor
that diminish PTH release at inappropriately low ionized calcium
concentrations have been found in familial hypocalcemia [22].
The elferent limb—Release of PTH from the parathyroid cell
The presence of a calcium-sensing protein within the plasma
membrane of the parathyroid cell permits it to detect changes in
extracellular ionized calcium concentration and to modify PTH
release accordingly. Activation of the receptor by its ligand, that
is, calcium, diminishes PTH release, whereas a reduction in
calcium receptor activity promotes PTH secretion [15—17]. The
parathyroid cell appears to be nearly unique among endocrine
tissues in that the rapid increase in intracellular calcium induced
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by activation of the calcium receptor diminishes rather than
stimulates hormone secretion. In other endocrine tissues, recep-
tor-activated, intracellular calcium transients generally initiate
hormonal release.
As ionized calcium levels fall, PTH that has previously been
synthesized and stored in secretoly granules within the parathy-
roid cell is released into the extracellular environment by exocy-
tosis. Available evidence indicates that the intact 1-84 amino acid
peptide is the predominant secretory product at reduced ionized
calcium levels [23—25]. In contrast, PTH release into the external
environment from the parathyroid cell diminishes when the
extracellular concentration of ionized calcium increases [9]. With
a half-life in the circulation of approximately 3 to 5 minutes,
serum intact PTH levels decline rapidly when serum ionized
calcium concentrations rise [9—13]. In addition to a reduction in
the amount of intact hormone released by exocytosis, PTH
undergoes degradation within the parathyroid cell under condi-
tions of calcium surfeit with the attendant release of inactive
carboxy-terminal peptide fragments [23—26].
Both a pulsatile pattern of PTH release and diurnal variations
in PTH secretion have been described in human subjects with
normal renal function [27, 28]. Similar studies have not been
done, however, in patients with secondary hyperparathyroidism. It
is not known, therefore, whether the pulsatile nature of PTH
release is preserved in secondary hyperparathyroidism or whether
differences in the frequency or amplitude of secretory bursts or
changes in the tonic level of PTH release contribute to the excess
PTH secretion that characterizes this disorder. Moreover, it
remains to be determined whether the normal diurnal variation in
PTH secretion is altered by the development of secondary hyper-
parathyroidism as recently described in patients with primary
hyperparathyroidism due to parathyroid adenoma [29].
Parathyroid hormone synthesis
The gene encoding mRNA transcripts for pre-pro-PTH resides
on chromosome 1 lq [30]. Several upstream sequences provide the
major regulatory control for gene transcription. One sequence,
which is located approximately 3.6 kilobases in the 5' direction
from the encoding region, down-regulates gene transcription in
response to calcium [31]. Another sequence, located 101 to 125
base pairs upstream from the first exon, binds to the vitamin D
receptor, providing a mechanism by which 1,25-dihydroxyvitamin
D can directly lower the rate of pre-pro-PTH gene transcription
[31—33].
Calcium and vitamin D, specifically 1,25-dihydroxyvitamin D,
have long been recognized as the two most important regulators
of serum PTH levels in vivo. It is now evident that each can modit'
gene transcription and PTH synthesis over periods of several
hours, ultimately reducing the amount of stored PTH within
secretory granules that is available for release from the parathy-
roid cell [34—37]. Calcium, however, has separate and immediate
effects on PTH release that are mediated through the calcium
receptor, whereas there is only limited evidence that 1,25-dihy-
droxyvitamin D affects the secretory response of parathyroid cells
to variations in ionized calcium concentration during short-term
incubations in vitro [38]; such findings are consistent with data
which indicate that 1,25-dihydroxyvitamin D does not alter
mRNA levels for the calcium-receptor in parathyroid cells al-
though there is some disagreement about this issue [39—41]. It is
likely, therefore, that 1,25-dihydroxyvitamin D acts primarily to
reduce PTH synthesis rather than to inhibit PTH release directly.
It is important to distinguish between the very rapid changes in
PTH secretion that are mediated through the calcium receptor
and the more sustained variations in hormone production that are
mediated at the transcriptional level by both calcium and 1,25-
dihydroxyvitamin D when considering the secretory behavior of
the parathyroid glands in chronic renal failure.
Modeling PTH secretion
As noted previously, parathyroid gland enlargement and alter-
ations in the regulation of PTH release by calcium may each
contribute to excess PTH secretion not only in secondary hyper-
parathyroidism due to chronic renal failure, but also in primary
hyperparathyroidism. To more fully evaluate the role of calcium
as a modifier of PTH secretion, Brown and co-workers developed
a four parameter working model that was subsequently applied
both to in vitro studies of dispersed parathyroid cells and to in vivo
studies of humans subjects [42—44]. Their approach utilized a
curve-fitting model to examine the inverse sigmoidal relationship
between ionized calcium concentration and PTH secretion anal-
ogous to those developed for the assessment of other physiologic
functions with non-linear properties such as enzyme kinetics and
ligand-receptor interactions. As such, the four parameter model
provided a method by which various components of PTH secre-
tion could be objectively quantified relative to changes in ionized
calcium concentration (vide infra) [42, 45, 46]. In this context, the
set point for calcium-regulated PTH release, or the mid point on
the ionized calcium-PTH curve, is an index of the amount of PTH
released across a range of ionized calcium levels [42].
The set point represents the ionized calcium concentration
around which variations in ionized calcium elicit changes in PTH
release. When the prevailing ionized calcium level is below the set
point, PTH secretion is enhanced, whereas PTH release dimin-
ishes when ionized calcium levels exceed the set point. The slope
of the mid portion of the inverse sigmoidal curve, which corre-
sponds to the range of ionized calcium concentrations near the set
point, is normally quite steep, and it reflects the sensitivity of the
parathyroid to changes in ionized calcium concentration; thus,
small deviations either above or below the set point elicit large
changes in PTH release. The upper and lower portions of the
inverse sigmoidal curve describe the limits of the parathyroid
secretory response to larger variations in ionized calcium concen-
tration. As ionized calcium levels deviate further from the set
point, both the stimulation of PTH release at low ionized calcium
levels and the inhibition of PTH release at high ionized calcium
levels reach definable limits, and greater increases or decreases in
serum ionized calcium do not produce additional changes in PTH
release.
In vitro assessments of PTH secretion
Results from early in vitro studies of dispersed parathyroid cells
indicated that the set point for calcium-regulated PTH release was
greater than normal in cells obtained from patients with primary
hyperparathyroidism [42—44], whereas less marked increases in
set point were found in parathyroid cells obtained from patients
with secondary hyperparathyroidism [47]. Although set point
values were only moderately elevated in cells obtained from
patients with secondary hyperparathyroidism, a greater propor-
tion of preparations had set point estimates that exceeded 1.03
mmol/liter compared to a mean value of 0.99 mmol/liter in normal
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parathyroid cells [47]. These in vitro observations using the four
parameter model provide the basis for the concept that the set
point for calcium-regulated PTH release is greater than normal
not only in primary hyperparathyroidism, but also in secondary
hyperparathyroidism due to chronic renal failure. As such, the
inverse sigmoidal curve depicting the relationship betveen ion-
ized calcium levels and PTH secretion is shifted to the right, and
higher in vitro concentrations of calcium are required to achieve
equivalent reductions in PTH release in parathyroid cells from
adenomatous or hyperplastic parathyroid glands [42—44, 47].
Since the renal production of 1,25-dihydroxyvitamin D, or
calcitriol, is impaired in advanced renal disease, disruption of the
normal feedback inhibition of PTH secretion by 1,25-dihydroxyvi-
tamin D represents an attractive potential mechanism to account
for an increase in the set point in secondary hyperparathyroidism.
Theoretical projections based upon the four parameter model
also indicate that variations in set point would have the greatest
impact on the prevailing level of PTH in serum and that an
increase in set point values could readily account for the markedly
elevated serum PTH levels that characterize patients with second-
ary hyperparathyroidism due to chronic renal failure 1421.
Changes in any one of the other three variables in the four
parameter model including the maximum PTH level, the mini-
mum PTH level and the slope of the inverse sigmoidal curve were
estimated to have less marked effects on basal serum PTH levels
[42].
Although conceptually appealing, 1,25-dihydroxyvitamin D has
not been shown to directly modify PTH release from parathyroid
cells in response to variations in ionized calcium concentration
during short-term incubations in vitro. Most available data indi-
cate that several hours or more of exposure to 1,25-dihydroxyvi-
tamin D is required to reduce PTH secretion in vitro, findings
consistent with the known genomic actions of this vitamin D sterol
[48].
In viva assessments of PTH secretion
Primary hyperparathyroidism
Brown and co-workers also applied the four parameter model
to in vivo studies of parathyroid gland function [43, 44]. To assess
the secretory behavior of the parathyroids in humans, serum
ionized calcium levels were raised by infusing calcium gluconate
and lowered by infusing either sodium EDTA or sodium citrate to
elicit reciprocal changes in serum PTH levels [10, 11, 43, 44]. The
results of these studies indicated that estimates of the set point
obtained in vivo in patients with primary hyperparathyroidism
corresponded to values subsequently determined in vitro in para-
thyroid cells from the same individuals harvested at the time of
parathyroid surgery. Such findings served to validate the four
parameter model for studies in humans, and several groups of
investigators have now confirmed that set point values are indeed
greater than normal in patients with primary hyperparathyroidism
as judged by in vivo assessments of parathyroid gland function
[49]. The regulation of PTH secretion by calcium is altered,
therefore, in primary hyperparathyroidism due to parathyroid
adenoma as judged both by in vitro and in vivo assessments
[42—44]. Disturbances in calcium-regulated PTH release have also
been documented using dynamic tests of PTH secretion in
patients with familial hypocalciuric hypercalcemia [50].
Secondary hyperparathyroidism
In recent years, dynamic tests of parathyroid gland function
have been widely used to examine the regulation of PTH release
by calcium in patients with chronic renal failure. Comparisons
have been done among hemodialysis patients with different types
of renal osteodystrophy [51], and the effect of calcitriol therapy on
the secretory behavior of the parathyroid glands in secondary
hyperparathyroidism has received considerable attention [52—54].
Unlike earlier in vitro assessments, however, direct comparisons
between patients with secondary hyperparathyroidism and sub-
jects with normal renal function using in vivo dynamic tests of
parathyroid gland function have only recently been reported [12,
13].
In contrast to data originally obtained in dispersed parathyroid
cells in vitro, Ramirez et a! found no differences in set point using
the four parameter model between normal subjects and dialysis
patients with secondary hyperparathyroidism documented by
bone biopsy [12]. Subsequently, Messa et al also failed to detect
an increase in the set point in adult patients with various degrees
of renal insufficiency when compared to subjects with normal
renal function [13]. Available evidence indicates, therefore, that
the set point does not differ from normal in patients secondary
hyperparathyroidism as judged by in vivo assessments of parathy-
roid gland function.
Although clearly at odds with data obtained using human
parathyroid cells in vitro, several important differences should be
recognized between the application of the four parameter model
for in vivo studies of human subjects and its use for in vitro studies
of dispersed parathyroid cells. For in vitro assessments, the total
number of parathyroid cells in a given preparation can be
separately confirmed, and the amount of PTH released into the
tissue culture medium at different ionized calcium levels can be
corrected for variations in cell number [42—44]. As such, in vitro
studies provide insight into the secretory response of individual
parathyroid cells.
Reliable non-invasive methods for measuring the size of the
parathyroid glands in humans are not yet available, however, and
the number of parathyroid cells that are actively secreting hor-
mone in vivo cannot be determined. Hence, the maximum PTH
level achieved at reduced ionized calcium concentrations reflects
not only the intrinsic secretory capacity of individual parathyroid
cells, but also the total number of cells available for secretion [12,
55]. Erroneous conclusions about the secretory behavior of the
parathyroids may be reached if the role of parathyroid gland mass
on serum PTH levels is ignored, and variations in serum PTH
levels during changes in ionized calcium in vivo are considered
only to represent differences in calcium-mediated PTH release at
the level of individual parathyroid cells.
Again, the variable measured for in vivo dynamic studies of
parathyroid gland function is the level of PTH in serum rather
than the amount of hormone secreted. Despite the use of
techniques that standardize data from subjects with widely differ-
ing serum PTH levels to a value that is 100% of the maximum
PTH level achievable during hypocalcemia, it is not possible to
distinguish whether variations in serum PTH levels in vivo are due
predominantly to differences in cell number, such as parathyroid
gland size, or to differences in the intrinsic secretory behavior of
individual parathyroid cells. Therefore, a distinct shortcoming of
in vivo dynamic tests of parathyroid gland function as currently
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applied is the inability to correct for variations in the size of the
parathyroid glands. Such methodological considerations may ac-
count for the disparity between in vivo findings in patients with
secondaiy hyperparathyroidism due to chronic renal failure in
whom basal serum PTH vary widely and those of in vitro studies
using defined numbers of cells obtained from hyperplastic para-
thyroid tissues; they also serve as a reminder of the limitations of
in vivo models for studying the physiology of PTH secretion.
Effect of calcitriol therapy
The results of recent studies that fail to document set point
abnormalities in patients with secondary hyperparathyroidism
prompt a reconsideration of previous work which suggests that
treatment with calcitriol lowers the set point for calcium-regulated
PTI-I release in such patients. This concept has strongly influenced
thinking about the pathogenesis of secondary hyperparathyroid-
ism in chronic renal failure and the role of calcitriol therapy in its
clinical management.
Delmez et al [53] and Dunlay et at [52] originally reported that
thrice weekly doses of intravenous calcitriol given over periods of
two and ten weeks, respectively, reduced the set point for
calcium-regulated PTH release in hemodialysis patients with
secondary hyperparathyroidism. Malberti, Surian and Cosci sub-
sequently reported similar results after four months of intrave-
nous calcitriol therapy [541; evidence that the set point was greater
than normal was not provided, however, in any of the three
studies. In contrast to these findings, Ramirez et al observed no
change in set point values after four months of treatment with
intermittent oral or intraperitoneal doses of calcitriol despite
marked reductions in basal serum PTH levels; set point estimates
before treatment also did not differ from normal in patients with
secondary hyperparathyroidism [56]. Similar findings have re-
cently been reported by Ouseph, Leiser and Moe after four weeks
of intravenous calcitriol therapy [57].
Methodological considerations may, in part, account for dis-
crepancies among these results. Ramirez et al used intravenous
infusions of sodium citrate or calcium gluconate to vary serum
ionized calcium levels in their patients with end-stage renal
disease [56], whereas most other investigators have employed
hemodialysis with either high or low dialysate calcium concentra-
tions to elicit changes in serum calcium levels [52—54]. Because
hemodialysis induces rapid changes in the serum levels of phos-
phorus, magnesium and glucose as well as in plasma pH and
osmolality, each of which can independently affect PTH release,
the two experimental techniques may not be equivalent for
assessing the secretory response of parathyroids [12]. A direct
comparison of results obtained by each method has yet to be
reported.
In addition, Ramirez et al utilized the four parameter model of
Brown et alto analyze their data, whereas others have employed
different models to evaluate results obtained during in vivo studies
of parathyroid gland function. For example, Delmez and co-
workers induced hypocalcemia and hypercalcemia during sepa-
rate hemodialysis sessions in individual study subjects, but only
results obtained during hemodialysis against a high dialysate
calcium were used to describe a shift in the ionized calcium-PTH
curve after treatment with calcitriol [53]. Most investigators have
considered the full range of PTH secretory responses under both
hypercalcemic and hypocalcemic conditions to derive estimates of
the set point. Moreover, Dunlay et a! [52] and Malberti et at [54]
have utilized an alternative approach to data analysis developed
by Felsenfeld and co-workers to examine the calcium-PTH sig-
moidal curve [58]. For this analysis, the definition of the set point
also differs substantially from that established by the four param-
eter model.
The four parameter model and alternative methods for
estimating the set point
Equation 1 describes the mathematical formula that relates
PTH values to ionized calcium levels using the four parameter
model. As originally developed by Delean and co-workers and
applied by Brown et al for in vitro studies [42, 46], estimates of the
amount of PTH released (Y) at any concentration of ionized
calcium (X) were obtained by measuring A, the maximum PTH
value observed at reduced ionized calcium levels; D, the minimum
PTH value observed at high concentrations of ionized calcium; C,
the set point, which is defined as the ionized calcium level at which
PTH values are midway between A and D; and B, the slope of the
sigmoidal curve at the set point [42, 46].
A-D
B+D1 + (X!C)
Assuming that observations for a given experiment indeed con-
form to a sigmoidal relationship, estimates of the set point
represent a method by which two or more curves can be com-
pared. In addition to marking the mid point of the inverse
sigmoidal curve, the set point also describes an intrinsic property
of the relationship between ionized calcium and PTH release as
determined by direct experimental observation, and it becomes a
constant in Equation 1 when solving for unknown values of Y.
Analogous terms for other approaches to the analysis of curvilin-
ear data include half-maximal activity, or Km, for enzyme kinetics
and binding affinity, or Kd, for ligand-binding curves.
For studies of PTH secretion in vivo, measurements of ionized
calcium and PTH obtained during the induction of hypocalcemia
and during calcium infusions are plotted together using a sigmoi-
dal curve-fitting model, and the ionized calcium level correspond-
ing to the midpoint of the calcium-PTH curve is determined by
regression analysis [10—12]. The set point for calcium-regulated
PTH release as defined by the four parameter model represents
the ionized calcium level at which PTH values are midway
between the maximum level achieved at low calcium concentra-
tions and the minimum level observed at high calcium concentra-
tions [42, 46].
The alternative method employed by Felsenfeld and Llach
defines the set point as the serum ionized calcium level at which
PTH values are 50% of the maximum level observed during
hypocalcemia [58]. Calcium and PTH measurements obtained
during separate hemodialysis sessions using either low or high
dialysate calcium levels are plotted together; rather than applying
a sigmoidal model for data analysis, however, a linear connection
is made between two points corresponding to PTH and ionized
calcium values that are 95% of the maximum PTH level observed
during hypocalcemia and 5% above the minimum PTH value
achieved during hypercalcemia. The set point is reported as the
ionized calcium level along the linear projection at which PTH
values are 50% of maximum [58].
Because PTH secretion persists even at very high ionized
calcium concentrations, PTH values rarely, if ever, fall to levels
that are 0% of maximum (Fig. 1). In subjects with normal renal
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Fig. 1. The inverse sigmoidal relationship
between serum ionized calcium and PTH levels in
20 normal subjects (•) and 13 patients with
secondaiy hyperparathyroidism (LI). Serum PTH
levels are expressed as a percentage of the
maximum value observed at reduced ionized
calcium concentrations. Serum PTH levels fall
to approximately 5% of maximum at high
ionized calcium levels in normal subjects,
whereas lesser reductions are seen in secondary
hyperparathyroidism. The lowest PTH levels
achievable in subjects with hyperplastic
parathyroid glands are approximately 20 to 25%
of maximum. Differences in the non-
suppressible component of PTH release
primarily account for the divergence of the two
1 .50 sigmoidal curves at high ionized calcium levels.
Reproduced with permission from reference
[12].
Fig. 2. Set point estimates for two non-parallel
sigmoidal curves as determined by the four
parameter model and by the alternative model of
Felsenfeld. The four parameter model defines
the set point as the ionized calcium level at
which PTH values are midway between
maximum (A) and minimum (D) values,
whereas the alternative model of Felsenfeld
defines the set point as the ionized calcium
level at which serum PTH levels are 50% of
maximum; differences in set point values
between curves are greater using this
1 .50 alternative approach. Symbols are: (—) curve
1; (— —
—) curve 2. Reproduced with permission
from reference [59].
tion are also likely to disagree with those obtained using the four
parameter model when comparing two sigmoidal curves that differ
with respect to the lowest PTH values achieved during hypercal-
cemia [59]. Indeed, such differences are a striking feature when
the ionized calcium-PTH curves for patients with secondary
hyperparathyroidism are compared to those of normal subjects
[12] (Figs. 1 and 2). The lower portions of the two curves diverge
as ionized calcium levels increase when PTH results are expressed
as a percentage of maximum values (Fig. 2). The upper portion of
each curve remains fixed, however, at 100%. The set point for the
sigmoidal curve with the higher minimum PTH values will,
therefore, be located above but only slightly to the right of the set
point for the adjacent curve when determined using the four
parameter model. In contrast to this result, the set point for the
uppermost curve becomes displaced further below its mid portion
when a PTH value that is 50% of maximum is used to define the
set point for both curves (Fig. 2). As such, differences between set
point values for two asymmetric curves may be overestimated with
this approach [12, 59].
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function, the lowest PTH levels achievable during calcium infu-
sions are approximately 5% of maximum, whereas values remain
considerably higher in patients with secondary hyperparathyroid-
ism [12]. Thus, serum PTH levels do not decline to values less
than 20 to 25% of maximum in patients with hyperplastic para-
thyroid glands even at high serum ionized calcium concentrations
(Fig. 1). Variations in the magnitude of the non-suppressible
component of PTH secretion are not considered, however, in the
model of Felsenfeld. Redefining the set point as the ionized
calcium level that corresponds to a PTH value that is 50% of the
maximum level observed during hypocalcemia positions the set
point on a lower portion of the inverse sigmoidal ionized calcium-
PTH curve. As such, set point estimates using this alternative
definition would be expected to be greater than those determined
by the four parameter model (Figs. I and 2). The magnitude of
this effect may be partially offset, however, when a linear rather
than a sigmoidal fit of the data are used to estimate the set point
or to calculate the slope of the ionized calcium-PTH curve [58].
Set point estimates using this alternative model of PTH secre-
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Four parameter model Fig. 4. The weight of parathyroid tissue removed at surgety in dialysis
Fig. 3. Relationship between set point estimates obtained using the four
parameter model and an alternative method in subjects with normal renal
.jhnction (0) and in patients with secondaty hypertension (S). The regres-
patients with either a diffuse or nodular pattern of parathyroid hyperplasia.
Parathyroidectomy was done for the management of progressive renal
osteodystrophy (adapted from [641).
sion line reflects the combined result for both groups. r = 0.30, NS.
The impact of these methodological variations on estimates of the
set point has not been addressed.
In a recent report, Pahi et al calculated the set point using both Most studies of PTH secretion, whether done in vitro or in vivo,
methods in a group of hemodialysis patients with secondary employ direct measurements of ionized calcium levels because of
hyperparathyroidism in whom dynamic tests of parathyroid gland its pivotal role in regulating PTH release; however, several reports
function were done during hemodialysis procedures [60]. Values by Felsenfeld and co-workers describe the relationship between
determined by the method of Felsenfeld were on average higher serum PTH levels and total rather than ionized serum calcium
than those obtained using the four parameter model, but a high levels [60—62]. The fraction of ionized calcium in serum may differ
degree of correlation between the two methods was reported, among subjects, and values change substantially if the pH of
suggesting that similar results are obtained with either method plasma does not remain constant. This issue is particularly
[60]. In contrast to these findings, much weaker agreement relevant for studies done during hemodialysis procedures when
between the two methods has been found by our group both in plasma pH increases substantially. Since the parathyroid cell
patients with secondary hyperparathyroidism and in normal sub- responds to changes in ionized calcium concentration, direct
jects when the calcium-PTH relationship was characterized using measurements, rather than indirect estimates, of this key deter-
infusions of sodium citrate or calcium gluconate to vary serum minant of PTH release are more suitable for in vivo studies of
ionized calcium levels (Fig. 3). Therefore, set point estimates parathyroid gland physiology. At a time when the molecular
determined by the four parameter model and the by method of mechanisms responsible for the control of PTH secretion by
Felsenfeld often differed in individual study subjects. calcium are rapidly being clarified, studies employing measure-
As noted previously, Ramirez et al found no increase in set ments of total serum calcium to assess the secretory behavior of
point in patients with secondary hyperparathyroidism, 1.24 0.06 the parathyroid glands provide limited additional information.
mmol/liter, compared to normal subjects, 1.21 0.04 mmol/liter Such considerations may account, at least in part, for the striking
(x SD), using the four parameter model [12]. When these data inconsistency among published results from this group of investi-
were re-evaluated using the alternative method of Felsenfeld, set gators that have variously reported that the set point decreases
point estimates were 1.22 0.03 and 1.20 0.02 mmol/liter, [52], remains unchanged [63] or increases [60] after treatment
respectively, in patients with secondary hyperparathyroidism and with calcitriol in patients with secondary hyperparathyroidism.
normal volunteers, and values again did not differ between
groups. Such findings indicate that differences in the method for Parathyroid gland hyperplasia
calculating the set point do not adequately account for the failure There is considerable heterogeneity among patients in the
to find a set point abnormality in vivo in patients with secondary severity of secondary hyperparathyroidism in chronic renal fail-
hyperparathyroidism using the four parameter model [12, 13, 56]. ure, and this variability may make it difficult to detect abnormal-
A recent analysis by Ouseph, Leiser and Moe reached similar ities in calcium-regulated PTH release when studies are done in
conclusions [57]. groups of unselected patients with secondary hyperparathyroid-
Although the calculations used in the foregoing comparison are ism. In this regard, the histologic subtype of parathyroid gland
based upon methods published by Felsenfeld and co-workers in hyperplasia may be an important consideration.
1993 [58], other reports from this same group of investigators have The nodular pattern of parathyroid hyperplasia is generally
used different parameters to derive values for the set point, associated with more extensive parathyroid gland enlargement as
Specifically, the upper and lower five percent of the sigmoidal judged by the weight of tissues removed from dialysis patients
curve has been excluded in some analyses to minimize distortions undergoing parathyroidectomy for the management of renal
that may be seen at the highest and lowest serum calcium levels osteodystrophy (Fig. 4) [64, 65]. Fukuda et al, using immunohis-
[58], whereas the upper and lower ten percent of the curve has tochemical methods, also reported that vitamin D receptor ex-
been excluded in other studies [60, 61]. In earlier reports, it pression was lower in the nodular than in the diffuse form of
appears that the full sigmoidal curve was evaluated [5, 52, 62]. parathyroid hyperplasia [66]. Such findings are of interest because
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Fig. 5. Set point values for volunteer subjects with normal renal fimction and
for 26 patients categorized as having mild, moderate or severe secondaty
hyperparathyroidism as judged by the basal level of serum PTH (Reproduced
with permission from /68]). The horizontal dashed line depicts the average
set point for all 26 patients evaluated.
of the widely recognized antiproliferative effects of 1,25-dihy-
droxyvitamin D in a variety of cells and tissues. Alterations in
vitamin D receptor expression may contribute, therefore, not only
to the severity of parathyroid gland hyperplasia in chronic renal
failure, but also to disturbances in the regulation of PTH release
by calcium.
Deletions on chromosome 11 and monoclonal expansion of
subpopulations of cells within the parathyroids represent addi-
tional factors that may influence parathyroid cell proliferation and
the degree of parathyroid gland enlargement in secondary hyper-
parathyroidism [6, 671. As such, it is possible that set point
abnormalities are confined to a subset of patients with more
advanced secondary hyperparathyroidism.
Although few studies have directly addressed this issue, our
group has found that set point estimates do not differ according to
the severity of secondary hyperparathyroidism in patients under-
going regular dialysis [68]. Values were no greater in patients with
markedly elevated serum PTH levels than in those with only
modestly high values when evaluated in vivo using the four
parameter model (Fig. 5). Therefore, the extent of parathyroid
gland hyperplasia, rather than alterations in the regulation of
PTH release by calcium, may be a more important determinant of
the excess PTH secretion that characterizes renal secondary
hyperparathyroidism. Preliminary data from Indridason and
Quarles are consistent with this view [69]; the degree to which
serum PTH levels could be lowered during hemodialysis against
high dialysate calcium concentrations was inversely related to the
size of the parathyroid glands as assessed by non-invasive radio-
graphic imaging techniques including magnetic resonance imaging
(MRI) [69].
Additional studies will be required to determine whether the
secretory behavior of the parathyroids differs in the nodular and
diffuse forms of parathyroid gland hyperplasia as judged by
estimates of the set point for calcium-regulated PTH release.
Evidence has recently been presented that calcium receptor
expression, as measured by immunohistochemical methods, is less
than normal both in parathyroid adenomas and in hyperplastic
parathyroid glands from patients with end-stage renal disease, but
the extent of the reduction in calcium receptor expression did not
correspond to the biochemical severity of hyperparathyroidism in
this initial report [70]. Overall, the degree of parathyroid gland
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Fig. 6. Serum PTH levels, expressed as a percentage of pre-infusion values,
during two-hour infusions of calcium gluconate in patients with either
secondaiy hyperparathyroidism (S) or adynamic lesions of renal osteodys-
trophy (LI). Values are means SEM. Results obtained in 20 subjects with
normal renal function (NL) are depicted by the dashed line (from [72];
used with permission).
enlargement, variations in calcium receptor expression and alter-
ations in the intrinsic secretory behavior of individual parathyroid
cells may each contribute to the excess PTH secretion character-
istic of secondary hyperparathyroidism due to chronic renal
failure. Abnormalities of PTH secretion that are associated with
specific genotypes remain a subject of considerable interest as
recently described in primary hyperparathyroidism [71].
PTH secretion in various forms of renal osteodystrophy
In addition to studies of secondary hyperparathyroidism, assess-
ments of calcium-regulated PTH release have also been made in
patients with different types of renal osteodystrophy [12, 51, 72].
Discrepancies among reports are likely to be, at least in part,
related to the methods employed for determining the set point
and to the availability of data obtained in subjects with normal
renal function with which to compare results.
Felsenfeld et al reported differences in set point values among
patients with secondary hyperparathyroidism and subjects with
adynamic lesions of renal osteodystrophy either with or without
evidence of bone aluminum deposition [51]. The set point for
calcium-regulated PTH release was also reported to increase in
patients with aluminum-related bone disease after successful
treatment with deferrioxamine [62]. In contrast to these findings,
Sanchez and co-workers found no evidence that the set point was
lower than normal in peritoneal dialysis patients with adynamic
skeletal lesions [72]. In this regard, separate assessments of the
secretory response to either increases or decreases in serum
ionized calcium concentration may provide more useful informa-
tion about parathyroid gland function in patients with chronic
renal failure than analyses that rely upon the four parameter
model or alternative models of PTH secretion [12, 56].
The degree to which PTH release can be lowered during
calcium infusions differs markedly in normal subjects and those
with secondary hyperparathyroidism (Fig. 6). When expressed as
a percentage of pre-infusion values to account for differences in
basal serum PTH levels, values decline more slowly in patients
with secondary hyperparathyroidism despite an equivalent rate of
rise in serum ionized calcium, and the lowest serum PTH levels
achievable during calcium infusions remain substantially above
those of normal subjects [12]. Factors that could account for such
differences in secondary hyperparathyroidism include a defect in
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Fig. 7. Serum PTH levels, expressed as a percentage of pre-infusion values,
during two-hour infusions of sodium citrate in patients with either secondary
hypeiparathyroidism (•) or adynamic lesions of renal osteodystrophy (E).
Values are means SEM; for data points without error bars, the SCM is
smaller than the size of the symbol. Results obtained in 20 normal subjects
(NL) are depicted by the dashed line. Asterisks denote differences
between patients with adynamic lesions and those with secondary hyper-
parathyroidism; < 0.05, **j) < 0.001.
the mechanism for sensing increases an the extracellular calcium
concentration, a prolongation of the serum half-life of PTH in
chronic renal failure and an overall reduction in the capacity of
enlarged parathyroid glands to lower basal levels of PTH release
[731.
It is not yet possible to distinguish among these possibilities;
mRNA levels for the calcium receptor are not diminished in the
parathyroid glands of rats with secondary hyperparathyroidism
induced either by chronic renal failure or by dietary calcium
restriction, suggesting that the molecular mechanism responsible
for regulating PTH release from the parathyroid cell in response
to changes in ionized calcium remains intact despite the develop-
ment of parathyroid gland hyperplasia [40]. As noted previously,
however, calcium receptor expression may be lower in hyperplas-
tic and adenomatous human parathyroid tissues [70]. A calcium-
sensing defect may be present, therefore, in at least of portion of
patients with secondary hyperparathyroidism as suggested by
earlier in vitro studies [42—44].
Recent evidence also indicates that the proportion of N-
terminal and carboxy-terminal PTH fragments in serum differs
substantially under hypocalcemic and hypercalcemic conditions,
changes that likely reflect alterations in the intracellular process-
ing of PTH prior to its release from the parathyroid cell [74, 75].
Therefore, a greater proportion of carboxy-terminal PTH frag-
ments is found in plasma when serum calcium levels are elevated.
It is also possible that the clearance of intact PTH from plasma is
less than normal in chronic renal failure. Such a change could
account for the slower decline in serum PTH levels during calcium
infusions in vivo when PTH is measured using assays for the intact
hormone, but this issue has yet to be fully evaluated. Additional
studies are required to determine whether in vivo measurements
of serum PTH levels actually reflect the rate of hormonal release
when serum ionized calcium level increase.
Despite markedly lower basal serum PTH levels, both the rate
of decline and the deree of PTH suppression during calcium
infusions is also less than normal in patients with adynamic lesions
of renal osteodystrophy. Whereas the parathyroid glands are
generally considered to be relatively inactive in such patients, the
response is similar both in direction and magnitude to that of
patients with secondary hyperparathyroidism when serum ionized
calcium levels rise (Fig. 6). As such, the same factors that blunt
the inhibitory secretory response to calcium in overtly hyperplastic
parathyroid glands may also account for the response to calcium
infusions in patients with adynamic lesions of renal osteodystro-
phy (Fig. 6).
In contrast to the results obtained during calcium infusions,
reductions in serum ionized calcium elicit markedly different in
vivo secretory responses in patients with secondary hyperparathy-
roidism and those with adynamic lesions (Fig. 7). Compared to
normal subjects, serum PTH levels increase much more slowly in
subjects with adynamic renal osteodystrophy despite an equivalent
decline in serum ionized calcium [72]. The average percentage
increase in serum PTH above pre-infusion values is greater,
however, than that observed in patients with secondary hyper-
parathyroidism, and the magnitude of response to hypocalcemia
approaches that seen in normal subjects (Fig. 7). After accounting
for differences in basal serum PTH levels, the secretory reserve of
the parathyroids in patients with the adynamic lesion appears to
be greater than that of subjects with secondary hyperparathyroid-
ism.
Alterations in functional parathyroid gland mass, or the amount
of parathyroid tissue that is actively secreting PTH, may contrib-
ute to the pattern of PTH release observed during the induction
of hypocalcemia in adynamic renal osteodystrophy. Fitzpatrick
and co-workers have suggested that the proportion of parathyroid
cells that secrete PTH in vitro increases as the concentration of
calcium in the culture medium is reduced [76]. When assessed by
the reverse hemolytic plaque assay, approximately 28% of dis-
persed bovine parathyroid cells release PTH when the medium
calcium concentration is 1.0 mrvi, but the percentage of actively
secreting cells increases progressively as calcium levels are low-
ered [76]. Conversely, higher concentrations of extracellular cal-
cium reduce the proportion of parathyroid cells that release PTH
in vitro, whereas the fraction of cells that synthesize hormone
remains constant across a wide range of calcium concentrations as
judged by immunohistochemical methods [761. Recruitment of
quiescent hormone-producing cells to active secretion may con-
tribute, therefore, to the normal secretory reserve of the parathy-
roids and other endocrine tissues [77].
Differences in the proportion of parathyroid cells that are
actively secreting PTH in parathyroid glands that are only mod-
erately enlarged may explain the lower basal serum PTH levels of
patients with adynamic lesions of renal osteodystrophy compared
to those with secondary hyperparathyroidism despite higher than
normal serum PTH values in both groups. Indeed, the pattern of
the decrease in serum PTH levels during calcium infusions
suggests that that the acute response to increases in extracellular
calcium in vivo may not differ substantially in these two disorders.
Summary
In vivo dynamic tests of parathyroid gland function have
provided useful information about the secretory behavior of
parathyroids in various clinical disorders, but the limitations of
this approach must be recognized when applied to studies of
parathyroid gland physiology. Set point abnormalities have been
documented in vivo both in primary hyperparathyroidism and in
familial hypocalciuric hypercalcemia. Such findings are consistent
with in vitro results obtained in studies of dispersed parathyroid
cells from patients with primary hyperparathyroidism and with
recently described alterations in calcium receptor expression in
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patients with FHH. The assessment of parathyroid gland function
in patients with end-stage renal disease presents distinct method-
ological problems, however, because of marked variation in the
degree of parathyroid gland enlargement. Neither the four pa-
rameter model originally used to describe set point abnormalities
both in vitro and in vivo or alternative approaches to the assess-
ment of PTH secretion in vivo adequately address this important
issue.
Results from recent in vivo studies of patients with chronic
renal failure do not support the view that the set point for
calcium-regulated PTH release is abnormal in secondary hyper-
parathyroidism or that treatment with calcitriol lowers the set
point for calcium-regulated PTH release in patients with uremic
secondary hyperparathyroidism. The concept of set point distur-
bances has strongly influenced discussions about the pathogenesis
of secondary hyperparathyroidism, and it has served as a focal
point for examining the therapeutic response to calcitriol in
patients with this disorder. This matter requires careful re-
consideration, however, in light of recent clinical findings and the
development of techniques to directly assess the molecular mech-
anisms responsible for regulating calcium-mediated PTH release
in renal failure and other disorders of mineral metabolism.
Although knowledge in this area remains limited, the extent of
parathyroid hyperplasia and the role of factors that influence the
development of parathyroid gland enlargement may ultimately
prove to be particularly important modifiers of parathyroid gland
function in chronic renal failure.
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